“CKD is not primarily a kidney disease — it is a cardiovascular disease that happens to manifest in the kidneys. The leading cause of death in dialysis patients is not kidney failure. It is heart disease.”
By Dr. Rahul Agarwal | Consultant Vascular & Endovascular Surgeon, CARE Hospitals, Banjara Hills, Hyderabad
Most people with chronic kidney disease (CKD) fear dialysis. What they should equally fear — and actively work to prevent — is cardiovascular disease. Patients with CKD have a cardiovascular mortality risk 10 to 20 times higher than the general population. In dialysis patients, cardiovascular disease accounts for approximately 40–50% of all deaths.
Understanding why this happens is the first step toward doing something about it.
🔧 Why CKD Devastates the Cardiovascular System
1. Uraemic Toxins and Endothelial Damage
Failing kidneys cannot adequately clear uraemic toxins — metabolic waste products that accumulate in the blood. These compounds — indoxyl sulphate, p-cresol sulphate, and others — directly damage the endothelium (inner lining of blood vessels), triggering inflammation, oxidative stress, and accelerated atherosclerosis.
2. Vascular Calcification
CKD causes profound disturbances in calcium and phosphate metabolism. High phosphate levels, low active vitamin D, and secondary hyperparathyroidism together drive calcium-phosphate crystal deposition into arterial walls. This medial arterial calcification makes vessels rigid, stiff, and non-compressible — dramatically increasing cardiac afterload and pulse wave velocity, leading to left ventricular hypertrophy.
This calcification also occurs in heart valves, coronary arteries, and the aorta. It is not the same as cholesterol-driven atherosclerosis — statins do not prevent it, though phosphate control and vitamin D analogues help.
3. Fluid Overload and Left Ventricular Hypertrophy
As kidney function declines, the ability to excrete sodium and water decreases. Fluid overload increases cardiac preload, chronically stretching and enlarging the heart muscle. This left ventricular hypertrophy is present in over 70% of dialysis patients and is itself a powerful independent predictor of sudden cardiac death.
4. Anaemia
CKD impairs erythropoietin production, causing anaemia. The heart compensates by working harder to deliver adequate oxygen — increasing cardiac output and further stressing an already compromised myocardium.
5. Hypertension — Both Cause and Consequence
Hypertension both causes and is worsened by CKD. As kidney function declines, renin-angiotensin-aldosterone system activation drives BP higher. Elevated BP then further damages the kidneys and the cardiovascular system in a reinforcing cycle.
🪸 The Vascular Surgeon’s Role in CKD Cardiovascular Risk
CKD patients frequently develop peripheral artery disease (PAD) at earlier ages and more severe stages than the general population — partly from accelerated atherosclerosis, partly from vascular calcification. They are also at high risk of aortic aneurysm, carotid disease, and renovascular hypertension.
As a vascular surgeon managing dialysis access, assessing AV fistula blood flow and cardiac output simultaneously can identify — a high-flow fistula in a patient with compromised cardiac function which can precipitate heart failure. Fistula flow optimisation is increasingly recognised as a cardiovascular intervention, not just a dialysis access one.
🛡️ What CKD Patients Can Do to Reduce Cardiovascular Risk
- Control blood pressure rigorously — target below 130/80 mmHg; every mmHg reduction matters
- Control phosphate through diet and binders — reduce processed foods, dark colas, and high-phosphate additives
- Treat anaemia — erythropoiesis-stimulating agents and iron correction reduce cardiac workload
- Statins — reduce cardiovascular events in early-to-mid CKD; benefit in dialysis patients is less clear but generally maintained in those already taking them
- Fluid management — sodium restriction and diuretics where kidney function allows; strict fluid targets on dialysis
- Avoid nephrotoxins — NSAIDs, excess contrast dye, aminoglycoside antibiotics all accelerate CKD and worsen cardiovascular risk
❓ Frequently Asked Questions
My CKD is Stage 3. Do I have significantly higher heart disease risk?
Yes. Cardiovascular risk rises at every stage of CKD and is already meaningfully elevated at Stage 3 (eGFR 30–60). The risk is not linear — it rises sharply as eGFR falls below 45, and again below 30. Aggressive risk factor control at Stage 3 delivers the greatest long-term benefit.
Why can’t statins prevent vascular calcification in CKD?
Statins reduce cholesterol-driven atherosclerotic plaque. Medial arterial calcification in CKD is driven by calcium-phosphate dysregulation — a fundamentally different mechanism. Phosphate binders, active vitamin D analogues (calcitriol, alfacalcidol), and calcimimetics are the relevant treatments. Your nephrologist manages this.
🔑 Key Insights: Cardiovascular disease is primary cause of mortality in 40–50% of dialysis patients and is 10–20 times more common in CKD than in the general population. The causes are unique to CKD: uraemic toxins, vascular calcification, fluid overload, anaemia, and hypertension. Statins help but don’t address calcification. Phosphate control, BP management, and anaemia treatment are the pillars of cardiovascular protection in CKD.
📚 Related Reading
- Dialysis Access & AV Fistula Surgery
- When Should a CKD Patient See a Vascular Surgeon?
- Vein Preservation in CKD
👨⚕️ About the Author
Dr. Rahul Agarwal is a Consultant Vascular & Endovascular Surgeon at CARE Hospitals, Banjara Hills, Hyderabad. He manages dialysis access and the vascular complications of CKD, working closely with nephrologists to address cardiovascular risk in kidney patients throughout all stages of their disease.
Medical Disclaimer: This article is intended for general patient education only and does not constitute individualised medical advice. Always consult a qualified medical professional for diagnosis and treatment specific to your condition.